Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676584 | 0.81 | AKR1B1 (0.37) | AKR1B1 | |
| SCHEMBL5834719 | 0.81 | AKR1B1 (0.37) | AKR1B1 | |
| SCHEMBL5676296 | 0.81 | AKR1B1 (0.37) | AKR1B1 | |
| SCHEMBL3441481 | 0.78 | AKR1B1 (0.34) | AKR1B1 | |
| SCHEMBL8002266 | 0.78 | LMNA (0.39) | AKR1B1 | |
| SCHEMBL8934913 | 0.77 | LMNA (0.42) | AKR1B1 | |
| SCHEMBL8934933 | 0.77 | LMNA (0.42) | AKR1B1 | |
| SCHEMBL18740409 | 0.76 | — | — | |
| SCHEMBL8025665 | 0.74 | LMNA (0.38) | — | |
| SCHEMBL9300148 | 0.74 | LMNA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790155-A | Threose nucleic acid antisense oligonucleotide and method thereof | 豪夫迈·罗氏有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-118434860-A | Threose nucleic acid antisense oligonucleotide and method thereof | 豪夫迈·罗氏有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-20260146278-A1 | Biological Substance Treatment Method, Reaction Detection Method, Biological Substance Treatment Apparatus, and Reaction Detection Apparatus | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2026-05-28 | — | — | US | disclosed |
| EP-4606907-A1 | BIOLOGICAL SUBSTANCE TREATMENT METHOD, REACTION DETECTION METHOD, BIOLOGICAL SUBSTANCE TREATMENT APPARATUS, AND REACTION DETECTION APPARATUS | Japan Science and Technology Agency (JP) | 2025-08-27 | — | — | EP | disclosed |
| CN-119790155-A | Threose nucleic acid antisense oligonucleotide and method thereof | 豪夫迈·罗氏有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-118434860-A | Threose nucleic acid antisense oligonucleotide and method thereof | 豪夫迈·罗氏有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240175020-A1 | COMPOSITIONS OF MODIFIED TREMS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-05-30 | — | — | US | disclosed |
| WO-2024085132-A1 | BIOLOGICAL SUBSTANCE TREATMENT METHOD, REACTION DETECTION METHOD, BIOLOGICAL SUBSTANCE TREATMENT APPARATUS, AND REACTION DETECTION APPARATUS | 国立研究開発法人科学技術振興機構 | 2024-04-25 | — | — | WO | disclosed |
| CN-117106887-A | Compositions and methods for diagnosing and treating tuberculosis | 塞弗德公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116635538-A | Compositions and methods for diagnosing and treating tuberculosis | 塞弗德公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116348767-A | Method for diagnosing tuberculosis and distinguishing active tuberculosis from latent tuberculosis | 西菲伊德公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-106029887-A | Materials and methods for treatment of pulmonary arterial hypertension | 格拉斯哥大学理事会 | 2016-10-12 | — | — | CN | disclosed |
| CN-105462984-A | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES | 2016-04-06 | — | — | CN | disclosed |
| CN-103168235-B | For analyzing the method for the existence of disease markers in experimenter's blood sample | STICHTING VU-VUMC (NL) | 2016-01-13 | — | — | CN | disclosed |
| CN-104703610-A | Modulation of androgen receptor expression | ISIS PHARMACEUTICALS INC | 2015-06-10 | — | — | CN | disclosed |
| CN-102448992-B | Stabilizing composition for immobilized biomolecules | LEUKOCARE AG | 2015-06-10 | — | — | CN | disclosed |
| CN-104284675-A | Novel binding molecules with antitumor activity | COVAGEN AG | 2015-01-14 | — | — | CN | disclosed |
| EP-2419110-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | Enzon Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2414520-A2 | METHODS OF MODULATING AN IMMUNE RESPONSE TO A VIRAL INFECTION | Altair Therapeutics, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010120861-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ENZON PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146278-A1 | Biological Substance Treatment Method, Reaction Detection Method, Biological Substance Treatment Apparatus, and Reaction Detection Apparatus | TACR1, TACR2, TNF | AKR1B1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.